Recursion articles
The drug developer`s latest capital raise, a $150 million private placement, comes during a difficult market environment.
The strongest companies can raise money in any environment.
Recursion Pharmaceuticals (RXRX) - Get Free Report recently raised $150 million in gross proceeds from a private placement of
Maxx Chatsko
I’m Anne Carpenter, a member of Recursion’s Scientific Advisory Board since 2014, a few months after the company was launched. I read Chris’ blog post reflecting on Recursion’s early days and thought I could tell my side of the story: watching Recursion get off the ground.
I feel a bit sheepish as I recall grilling Recursion co-founders Chris Gibson and Blake Borgeson the day we first met in October 2013. I was almost seven years into leading my o
Anne Carpenter
By applying a proprietary operating system to drug discovery, the Utah clinical-stage biotechnology company expects to turn drug discovery from sequential testing into a search problem.
Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small molecule or biological therapeutic, initially a hit that, through further validation and evolution, can become a develop
Jonathan D Grinstein
It was great to be back in person at the 2022 BIO International Convention this year. It came as no surprise to us at Recursion that artificial intelligence (AI) and machine learning (ML) were hot topics at the conference, with more than half a dozen sessions exploring how these technologies are driving digital transformation in biopharma.
We heard from leaders who are applying AI at various stages across the drug discovery and development process. While the app
Shafique Virani
Recursion is entering an exciting period in our evolution as a clinical-stage biotechnology company. We recently announced that we’ve enrolled the first patient in the first human efficacy trial in our company’s history — a significant milestone for us, and for the patients we hope to serve.
Our Phase 2 trial is investigating the treatment of a disease called cerebral cavernous malformation (CCM), a devastating neurovascular disease. This pr
Chris Gibson